Monte Carlo study on the gold and gadolinium nanoparticles radio-sensitizer effect in the prostate ¹²⁵I seeds radiotherapy

[1] Wisely CE, Hadziahmetovic M, Reem RE, et al. Long-term Visual Acuity Outcomes in Patients with Uveal Melanoma Treated with ¹²⁵I Episcleral OSU-Nag Plaque Brachytherapy. Brachytherapy. 2016;15(1):12–22.10.1016/j.brachy.2015.09.013499081526525215Search in Google Scholar

[2] Liu P, Tong T, Huo B, et al. CT-guided ¹²⁵I brachytherapy for recurrent ovarian cancer. 2017;8(35):59766–59776.10.18632/oncotarget.15905560177628938680Search in Google Scholar

[3] Chen F, Wang D. Inhibition of glioblastoma growth and invasion by ¹²⁵I brachytherapy in rat glioma model. Am J Transl Res. 2017;9(5):2243-2254.Search in Google Scholar

[4] Mazeron R, Bajard A, Montbarbon X, et al. Permanent ¹²⁵I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence. Radiat Oncol. 2012;7:45-46.10.1186/1748-717X-7-46334215722449081Search in Google Scholar

[5] Jiao D, Wu G, Ren J, Han X. Radiofrequency ablation versus ¹²⁵I-seed brachytherapy for painful metastases involving the bone. Oncotarget. 2016;7(52): 87523-87531.10.18632/oncotarget.11983535000727636995Search in Google Scholar

[6] Lin L, Guo L, Zhang W, et al. Novel Silicone-Coated ¹²⁵I Seeds for the Treatment of Extrahepatic Cholangiocarcinoma. PLoS One. 2016;11(2):e0147701.10.1371/journal.pone.0147701474041726840346Search in Google Scholar

[7] Yao L, Cao Q, Wang J, et al. CT-Guided ¹²⁵I Seed Interstitial Brachytherapy as a Salvage Treatment for Recurrent Spinal Metastases after External Beam Radiotherapy. Biomed Res Int. 2016;2016:8265907.10.1155/2016/8265907522044928105434Search in Google Scholar

[8] Patel KR, Prabhu RS, Switchenko JM, et al. Visual acuity, oncologic, and toxicity outcomes with ¹⁰³Pd vs. ¹²⁵I plaque treatment for choroidal melanoma. Brachytherapy. 2017;16(3):646–653.10.1016/j.brachy.2017.01.012558603928262517Search in Google Scholar

[9] Stish BJ, Davis BJ, Mynderse LA, et al. Low dose rate prostate brachytherapy. Transl Androl Urol. 2018;7(3):341-356.10.21037/tau.2017.12.15604374030050795Search in Google Scholar

[10] Xiang Z, Mo Z, Li G, et al. ¹²⁵I brachytherapy in the palliation of painful bone metastases from lung cancer after failure or rejection of conventional treatments. Oncotarget. 2016;7(14):18384-18393.10.18632/oncotarget.7584495129526919235Search in Google Scholar

[11] Lee YC, Lin SC, Kim Y. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using ¹²⁵I COMS plaques. Radiat Oncol. 2018;13(1):221.10.1186/s13014-018-1166-z623469230424782Search in Google Scholar

[12] Zhu Y, Dong M, Yang J, Zhang J. Evaluation of Iodine-125 Interstitial Brachytherapy Using Micro-Positron Emission Tomography/Computed Tomography with 18F-Fluorodeoxyglucose in Hepatocellular Carcinoma HepG2 Xenografts. Med Sci Monit. 2019;25:371-380.10.12659/MSM.912590Search in Google Scholar

[13] Teles P, Barros S, Cardoso S, et al. A dosimetric study of prostate brachytherapy using Monte Carlo simulations with a voxel phantom, measurements and a comparison with a treatment planning procedure. Radiat Protect Dosim. 2015;165(1-4):482-487.10.1093/rpd/ncv055Search in Google Scholar

[14] Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11:6-19.10.1016/j.brachy.2011.07.005Search in Google Scholar

[15] Wang C, Chen Z, Sun W, et al. Palliative treatment of pelvic bone tumors using radioiodine (¹²⁵I) brachytherapy. World J Surg Oncol. 2016;14:294.10.1186/s12957-016-1050-ySearch in Google Scholar

[16] Tan Q, Qin Q, Yang W, et al. Combination of ¹²⁵I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study. Medicine (Baltimore). 2016;95(44):e5302.10.1097/MD.0000000000005302Search in Google Scholar

[17] Han Q, Deng M, Lv Y, Dai G. Survival of patients with advanced pancreatic cancer after iodine-125 seeds implantation brachytherapy: A meta-analysis. Medicine (Baltimore). 2017;96(5):e5719.10.1097/MD.0000000000005719Search in Google Scholar

[18] Rivard JM, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31(3):1-42.10.1118/1.1646040Search in Google Scholar

[19] Luxton G. Comparison of radiation dosimetry in water and in solid phantom materials for ¹²⁵I and ¹⁰³Pd brachytherapy sources: EGS4 Monte Carlo study. Med. Phys. 1994;21(5):631-641.10.1118/1.597317Search in Google Scholar

[20] Chiu-Tsao ST, Anderson LL, O’Brien K, Sanna R. Dose rate determination for ¹²⁵I seeds. Med Phys.1990;17(5):817-825.10.1118/1.596586Search in Google Scholar

[21] Chiu-Tsao ST, Anderson LL. Thermoluminescent dosimetry for Pd-103 (model 200) in solid water phantom. Med Phys.1991;18(3):449-452.10.1118/1.596692Search in Google Scholar

[22] Wang R, Sloboda RS. Monte Carlo dose parameters of brachyseed model LS-1 I-125 brachytherapy source. Applied Radiat Isotopes. 2001;56:805-813.10.1016/S0969-8043(02)00051-9Search in Google Scholar